Thursday, March 31, 2011

Gilead in potential $100M cancer deal with Yale

Gilead Sciences Inc. will pay $40 million over four years and possibly $100 million total over a decade in a cancer research deal with Yale University.
Foster City-based Gilead (NASDAQ: GILD) will work with the New Haven Ivy League school on studying the genetic basis and molecular mechanisms of cancer. Gilead’s first $40 million will be spread over four years, to be spent on basic research and infrastructure. If the project seems fruitful, Gilead will then pay the remaining $60 million over six more years.

No comments:

Post a Comment